Cargando…
Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma
INTRODUCTION: Transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate-stage hepatocellular carcinoma (HCC). For patients without an adequate response, current finding suggests that treatment with molecular target agents, approved for advanced stage, might pr...
Autores principales: | Ferreira-Silva, Joel, Costa-Moreira, Pedro, Cardoso, Helder, Liberal, Rodrigo, Pereira, Pedro, Macedo, Guilherme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891150/ https://www.ncbi.nlm.nih.gov/pubmed/36743988 http://dx.doi.org/10.1159/000520530 |
Ejemplares similares
-
Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020) -
Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020) -
Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020) -
Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma
por: Roth, Gael S., et al.
Publicado: (2022) -
Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study
por: Yoon, Jun Sik, et al.
Publicado: (2019)